Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Co-Diagnostics Q3 2026 Results: Net Loss of $6.31M, Loss Widens

Co-Diagnostics, Inc. reported a net loss of $21.7 million for the nine months ended September 30, 2026, compared to a $21.2 million loss in the prior year. Total revenue increased to $594,966 from $358,567, while cash and cash equivalents significantly decreased to $714,803 from $11.9 million at the start of the year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.30.1
Gross profit-0.00.1
Profit before tax-6.3-7.1
Net income-6.3-5.9
EPS (diluted, $ a share)$-1.01$-4.66

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+94.6%
Gross margin-7.2%
Source

10-Q filed with the SEC, NASDAQ: CODX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Co-Diagnostics, Inc.: key numbers

Share price
$0.2249Close, Nov 16
Market cap
$2.36M
Shares outstanding
10.51MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Co-Diagnostics, Inc.

All →
5:01 PM ET 8-K
Shareholder Meeting

Co-Diagnostics Shareholder Meeting

Co-Diagnostics held a court-ordered special meeting of shareholders on November 13, 2026, where shareholders elected five directors and approved an amendment to the 2025 Equity Incentive Plan. The amendment increases the number of shares authorized for issuance under the plan by 2,000,000 shares, bringing the total maximum to 2,223,333 shares. Shareholders also approved a non-binding advisory resolution regarding executive compensation.

8:02 AM ET 8-K
Financial Results

Co-Diagnostics Financial Results

Co-Diagnostics reported Q3 2026 financial results, highlighting a 12% year-over-year reduction in operating expenses and the submission of a 510(k) premarket notification to the FDA for its Flu A/B & RSV test. The company also expanded its platform capabilities through a collaboration with ReadyGo Diagnostics and the launch of cloud infrastructure in India.

Term
Q3 2026
4:16 PM ET 8-K
Shareholder Meeting

Co-Diagnostics Shareholder Meeting

Co-Diagnostics, Inc. reconvened its 2026 Annual Meeting of Stockholders on October 14, 2026, but was unable to transact business because a quorum was not present. The company determined not to adjourn the meeting again and intends to seek stockholder approval for the proposals at a future special meeting.

6:10 AM ET 8-K/A
Loan & Debt

Co-Diagnostics $3.1M Debt Financing with J.J. Astor & Co.

Co-Diagnostics, Inc. entered into a loan agreement with J.J. Astor & Co. for an aggregate principal funding amount of up to $3.1 million, with an initial $2.1 million funded at closing. The debt is structured as senior secured convertible installment promissory notes with a 1.35x factor rate, payable in 30 weekly installments and secured by substantially all company assets.

Value
$3.1M
Counterparty
J.J. Astor & Co.
Term
30 weeks
6:10 AM ET 8-K
Loan & Debt

Co-Diagnostics $3.1M Debt Financing with J.J. Astor & Co.

Co-Diagnostics entered into a senior secured convertible loan agreement with J.J. Astor & Co. for an aggregate principal funding amount of up to $3.1 million. The initial funding of $2.1 million resulted in a promissory note with an original principal amount of $2.835 million, reflecting a 1.35x factor rate, and is secured by substantially all of the company's assets.

Value
$3.1M
Counterparty
J.J. Astor & Co.
Term
30 weeks
6:02 AM ET 8-K
Shareholder Meeting

Co-Diagnostics Shareholder Meeting

Co-Diagnostics, Inc. announced that its 2026 Annual Meeting of Stockholders has been adjourned for a third time to October 14, 2026, due to a failure to achieve a quorum. The company was unable to transact any business at the original September 3 meeting or the subsequent adjournments on September 24 and September 30. Stockholders of record as of the original July 14, 2026 record date remain eligible to vote at the reconvened meeting.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.